{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-003192","form_type":"8-K","ticker":"XBIO","cik":"0001534525","company_name":"Xenetic Biosciences, Inc.","filed_at":"2024-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.881173+00:00","generated_at":"2026-06-02T03:39:17.376037+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Xenetic Biosciences reports Q1 2024 net loss of $1.2M; cash at $7.8M","bullets":["Net loss of approximately $1.2M for Q1 2024; R&D expenses up 58.6% to $0.9M on DNase preclinical work.","Ended quarter with $7.8M cash; advancing DNase oncology program towards Phase 1 for solid tumors.","Expects multiple preclinical data readouts in H2 2024 to guide clinical development strategy.","G&A expenses decreased 9.8% to $0.8M compared to prior year quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-003192","json":"https://secwatch.observer/filing/0001683168-24-003192.json","markdown":"https://secwatch.observer/filing/0001683168-24-003192.md","text":"https://secwatch.observer/filing/0001683168-24-003192.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534525/000168316824003192/0001683168-24-003192-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534525/000168316824003192/xenetic_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T03:39:17.376037+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"07c252bf4bc5fee3f8671fdc8f717dadcc75c56c","claim":"Xenetic Biosciences, Inc. reported first quarter of 2024 results: net income Net loss for the quarter ended March 31, 2024 was approximately $1.2 million..","evidence_excerpt":"On May 10, 2024, Xenetic Biosciences, Inc. (the “Company”) issued a press release announcing results for the three months ended March 31, 2024 and providing a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534525/000168316824003192/0001683168-24-003192-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2024"},{"label":"Net income","value":"Net loss for the quarter ended March 31, 2024 was approximately $1.2 million."},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}